Pfizer, Chicago Sign Agreement Governing Sales Of Opioids
(Agreement available. Document #28-160714-021P.)
In the voluntary “separate agreement pursuant to release agreement” signed June 30, Pfizer agreed not to make false or misleading claims about its opioid drugs, to include information about the risk of addiction, not to promote opioids for off-label uses, to disclose the design of clinical studies for opioids, to maintain a...
To view the full article, register now.